Finance

Lists
GETI-B:STO
Getinge publ AB
SEK 281.60
+0.57%
(+1.60) 1D
Nov 13, 5:29:52 PM GMT+1  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for GETI-B...
Open
SEK 280.20
High
SEK 281.70
Low
SEK 278.70
Mkt. cap
71.57B
Avg. vol.
535.48K
Volume
0.00
Dividend
1.69%
Quarterly dividend
SEK 1.19
Ex-dividend date
Apr 22, 2026
P/E ratio
27.13
52-wk high
SEK 283.00
52-wk low
SEK 175.90
EPS
SEK 10.38
Shares outstanding
254.15M
No. of employees
12K
Open
SEK 280.20
High
SEK 281.70
Low
SEK 278.70
Mkt. cap
71.57B
Avg. vol.
535.48K
Volume
0.00
Dividend
1.69%
Quarterly dividend
SEK 1.19
Ex-dividend date
Apr 22, 2026
P/E ratio
27.13
52-wk high
SEK 283.00
52-wk low
SEK 175.90
EPS
SEK 10.38
Shares outstanding
254.15M
No. of employees
12K
News stories
From web sources and news partners
Profile
Getinge AB is a publicly traded Swedish medical technology company. The company produces and distributes medical products and equipment for the healthcare and life sciences industries. The company is divided into three business areas: Life Science, Acute Care Therapies, and Surgical Workflows. The group employs approximately 12,000 people worldwide. The CEO of the company is Mattias Perjos, and the chairman of the board is Johan Malmquist. With a sales share of around 40%, the United States is by far the most important market for the company due to significantly higher prices and margins there. China and various Western European countries follow. Wikipedia
About Getinge publ AB
CEOMattias Perjos
Employees11.8K
Founded1904
Headquarters-
SectorHealth Care
IndustryMedical device
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
10.19B
7.44B
8.38B
8.45B
Cost of goods sold
5.38B
3.84B
3.96B
4.38B
Cost of revenue
5.38B
3.84B
3.96B
4.38B
Research and development expenses
484.00M
328.00M
358.00M
363.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.76B
2.55B
2.71B
2.58B
Operating expense
3.10B
2.87B
3.06B
2.93B
Total operating expenses
8.49B
6.70B
7.03B
7.31B
Operating income
1.70B
738.00M
1.35B
1.14B
Other non operating income
-105.00M
-1.00M
-
-1.00M
EBT including unusual items
1.21B
572.00M
1.15B
973.00M
EBT excluding unusual items
1.26B
602.00M
1.22B
1.00B
Income tax expense
338.00M
170.00M
312.00M
248.00M
Effective tax rate
28.03%
29.72%
27.11%
25.49%
Other operating expenses
-136.00M
-12.00M
-
-18.00M
Net income
868.00M
401.00M
841.00M
719.00M
Net profit margin
8.52%
5.39%
10.03%
8.51%
Earnings per share
4.45
1.80
3.59
3.10
Interest and investment income
73.00M
-
-
-
Interest expense
-103.00M
-135.00M
-133.00M
-134.00M
Net interest expenses
-30.00M
-135.00M
-133.00M
-134.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.97B
1.01B
1.63B
1.44B
Gain or loss from assets sale
40.00M
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps